European Union - English - EMA (European Medicines Agency)

mylan s.a.s. - lopinavir/ritonavir - hiv infections - antivirals for systemic use, - lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infected adults, adolescents and children above the age of 2 years.the choice of lopinavir/ritonavir to treat protease inhibitor experienced hiv-1 infected patients should be based on individual viral resistance testing and treatment history of patients.

European Union - English - EMA (European Medicines Agency)

mylan s.a.s. - rasagiline tartrate - parkinson disease - anti-parkinson drugs - rasagiline mylan is indicated for the treatment of idiopathic parkinson’s disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

constar x pty ltd - 35035 - electrode, electrocardiograph, single use - a single use electrical conductor that is applied to the surface of the body to transmit the electrical signal on the body surface to a processor, which produces a graphic representation of the electrical activity of the organ - eg the heart.

European Union - English - EMA (European Medicines Agency)

biopartners gmbh - somatropin - growth - pituitary and hypothalamic hormones and analogues, somatropin and somatropin agonists - somatropin biopartners is indicated for the replacement therapy of endogenous growth hormone in adults with childhood- or adult-onset growth-hormone deficiency (ghd).adult-onset: patients with ghd in adulthood are defined as patients with known hypothalamic-pituitary pathology and at least one additional known deficiency of a pituitary hormone excluding prolactin. these patients should undergo a single dynamic test in order to diagnose or exclude a ghd.childhood-onset: in patients with childhood-onset isolated ghd (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be performed after completion of growth, except for those having low insulin-like-growth-factor-i (igf-i) concentrations (< -2 standard-deviation score (sds)), who may be considered for one test. the cut-off point of the dynamic test should be strict.

Canada - English - Health Canada

cheplapharm arzneimittel gmbh - nilutamide - tablet - 50mg - nilutamide 50mg - antineoplastic agents

Canada - English - Health Canada

mylan pharmaceuticals ulc - cyproterone acetate - tablet - 50mg - cyproterone acetate 50mg - other miscellaneous therapeutic agents

Canada - English - Health Canada

curium canada inc - thallium chloride(ti 201) - solution - 37mbq - thallium chloride(ti 201) 37mbq - roentgenography

Malta - English - Medicines Authority

bioton sa 5 staroscinska str. 02-516 warsaw, poland - solution for injection - insulin human (rdna) 100 iu - drugs used in diabetes

Malta - English - Medicines Authority

bioton sa 5 staroscinska str. 02-516 warsaw, poland - solution for injection - insulin human (rdna) 100 iu/ml - drugs used in diabetes

Malta - English - Medicines Authority

bioton sa 5 staroscinska str. 02-516 warsaw, poland - suspension for injection - insulin human (rdna) 100 iu/ml - drugs used in diabetes